kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
482
JPY
+2
(+0.42%)
Dec 12, 3:30 pm JST
3.09
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
135.0
PBR
3.59
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
480 JPY 3.08 USD
Previous Close Dec 11
480 JPY 3.07 USD
High Dec 12, 12:30 pm
483 JPY 3.10 USD
Low Dec 12, 12:30 pm
478 JPY 3.06 USD
Volume
53,300
Trading Value
0.03B JPY 0.16M USD
VWAP
480.06 JPY 3.08 USD
Minimum Trading Value
48,200 JPY 309 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
93
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
288
1-Year High Apr 22, 2025
11,342
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 71,900 573,500 7.98
Nov 28, 2025 63,900 457,800 7.16
Nov 21, 2025 66,200 460,100 6.95
Nov 14, 2025 72,000 480,800 6.68
Nov 7, 2025 76,600 509,200 6.65
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.